Mirtazapine Discontinuation: Moderate Difficulty with Withdrawal Risk
Mirtazapine can be moderately difficult to discontinue, particularly if stopped abruptly, as it carries a documented risk of discontinuation syndrome that requires gradual tapering to minimize withdrawal symptoms.
Understanding the Withdrawal Risk
The FDA drug label explicitly warns about discontinuation syndrome with mirtazapine 1. Abrupt cessation can produce clinically significant withdrawal symptoms including dizziness, abnormal dreams, sensory disturbances (paresthesia and electric shock sensations), agitation, anxiety, fatigue, confusion, headache, tremor, nausea, vomiting, and sweating 1.
Evidence from Clinical Practice
A documented case report demonstrates the real-world impact: a 53-year-old man taking just 15 mg/day (a low dose) experienced acute withdrawal symptoms within 48 hours of inadvertent abrupt discontinuation, including anxiousness, nausea, tremor, complete loss of appetite, and 8-pound weight loss over 14 days. His symptoms resolved immediately upon restarting mirtazapine 2. This case is particularly instructive because it occurred at a low dose used for appetite stimulation, not depression.
Comparison to Other Antidepressants
While mirtazapine shares discontinuation risks with other second-generation antidepressants 3, the evidence suggests it may be somewhat easier to discontinue than SSRIs. A large systematic review found more robust evidence for SSRI withdrawal symptoms (including withdrawal syndrome, vertigo, dizziness, and suicidal ideation) compared to limited withdrawal data for other antidepressant classes including mirtazapine 4.
Safe Discontinuation Strategy
The FDA label mandates gradual dose reduction rather than abrupt cessation 1. Based on general antidepressant discontinuation principles:
- Taper slowly over several days to weeks to reduce withdrawal risk 5
- Monitor closely for 2-4 weeks after final dose, as withdrawal symptoms can emerge days to weeks after discontinuation 6
- Consider extending the taper period if withdrawal symptoms emerge during dose reduction
- Do not assume symptom return represents relapse - withdrawal symptoms often occur in the final tapering stages and should be distinguished from disease recurrence 7
Key Clinical Pitfalls
Don't mistake withdrawal for relapse: Withdrawal symptoms (dizziness, sensory disturbances, anxiety) can mimic depression/anxiety recurrence but typically have acute onset related to dose reduction 1, 7
Low doses still require tapering: The case report demonstrates that even 15 mg/day can produce significant withdrawal 2
Provide patient education: Normalize the tapering process and set realistic expectations to reduce nocebo effects 7
Plan adequate monitoring: Symptoms may not manifest immediately - maintain follow-up for several weeks post-discontinuation 6
Bottom Line
Mirtazapine is moderately difficult to discontinue and requires gradual tapering to avoid withdrawal syndrome. While potentially easier than SSRIs, it still carries documented risk of clinically significant withdrawal symptoms even at low doses. Never stop mirtazapine abruptly - always implement a gradual taper with close monitoring 1, 2.